COVID-19重症患者炎症、高凝与巨噬细胞活化临床生物标志物与谵妄的关系
这项回顾性观察性队列研究纳入2020年3月1日至6月7日两家大型城市学术转诊医院ICU收治的197例COVID-19成人患者,每日检测CRP、d-二聚体和铁蛋白,每日两次评估昏迷(Richmond躁动-镇静量表)和谵妄(ICU意识模糊评估法/ICU意识模糊评估法-7)。d-二聚体四分位升高(OR 1.57;95%CI 1.17-2.12;p<0.01)和铁蛋白四分位升高(OR 1.36;95%CI 1.02-1.81;p<0.01)与次日谵妄/昏迷复合结局风险增加相关。CRP四分位升高与次日昏迷(OR 1.36;95%CI 1.03-1.79;p=0.030)和谵妄严重程度(β=0.30;se 0.07;p≤0.01)相关。作者认为这是假设生成性研究,需要更大规模研究验证。
要点
- 在197例COVID-19 ICU患者中,d-二聚体四分位升高与次日谵妄/昏迷复合结局风险增加相关(OR 1.57;95%CI 1.17-2.12;p<0.01)。
- 铁蛋白四分位升高与次日谵妄/昏迷复合结局风险增加相关(OR 1.36;95%CI 1.02-1.81;p<0.01)。
- d-二聚体与次日谵妄(OR 1.49;95%CI 1.14-1.94;p<0.01)和昏迷(OR 1.52;95%CI 1.08-2.14;p=0.017)独立相关。
- 铁蛋白四分位升高与次日谵妄(OR 1.33;95%CI 1.04-1.70;p=0.026)和昏迷(OR 1.59;95%CI 1.14-2.23;p<0.01)独立相关。
- CRP四分位升高与次日昏迷(OR 1.36;95%CI 1.03-1.79;p=0.030)及谵妄严重程度(β=0.30;se 0.07;p≤0.01)相关。
适用人群与场景
- 2020年3月1日至2020年6月7日入住两家大型城市学术转诊医院ICU的所有连续成人COVID-19患者,且进行了临床生物标志物检测和谵妄评估。
研究设计与关键结果
- 研究类型:回顾性观察性队列研究;场景:两家大型城市学术转诊医院ICU;纳入197例COVID-19 ICU成人患者。
- 干预:无;每日检测CRP、d-二聚体和铁蛋白浓度,每日两次评估昏迷(Richmond躁动-镇静量表)和谵妄(ICU意识模糊评估法/ICU意识模糊评估法-7)。
- 主要复合终点:d-二聚体四分位升高与次日谵妄/昏迷复合结局风险增加相关(OR 1.57;95%CI 1.17-2.12;p<0.01);铁蛋白四分位升高与次日谵妄/昏迷复合结局风险增加相关(OR 1.36;95%CI 1.02-1.81;p<0.01)。
- 独立终点:d-二聚体与次日谵妄独立相关(OR 1.49;95%CI 1.14-1.94;p<0.01),与次日昏迷独立相关(OR 1.52;95%CI 1.08-2.14;p=0.017)。
- 独立终点:铁蛋白四分位升高与次日谵妄独立相关(OR 1.33;95%CI 1.04-1.70;p=0.026),与次日昏迷独立相关(OR 1.59;95%CI 1.14-2.23;p<0.01)。
- CRP四分位升高与次日昏迷相关(OR 1.36;95%CI 1.03-1.79;p=0.030),与次日谵妄严重程度相关(β=0.30;se 0.07;p≤0.01)。
证据类型、等级与局限
- 证据类型:回顾性观察性队列研究;作者称其为假设生成性研究。
- 局限:作者指出需要更大规模的研究来验证这些结果。
对床旁实践的改变
- 作者认为该假设生成性研究提示d-二聚体和铁蛋白与次日谵妄/昏迷相关,CRP与次日昏迷及谵妄严重程度相关;需要更大规模研究验证这些结果。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: Critically ill patients with COVID-19 experience high rates of delirium and coma. Whether delirium occurs through novel mechanisms in COVID-19 is not known. We analyzed the relationship among biomarkers of inflammation (C-reactive protein [CRP]), hypercoagulability (d-dimer), and lung macrophage activation (ferritin), and the primary composite outcome of delirium/coma next day. We also measured associations between biomarkers and next day delirium and coma independently, and delirium severity.
DESIGN: Retrospective, observational cohort study.
SETTING: ICUs at two large, urban, academic referral hospitals.
PATIENTS: All consecutive adult patients admitted to the ICU from March 1, 2020, to June 7, 2020, with COVID-19 with clinical biomarkers and delirium assessments performed.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Daily concentrations of CRP, d-dimer, and ferritin were obtained. Coma (assessed by Richmond Agitation-Sedation Scale) and delirium (assessed by Confusion Assessment Method for the ICU/Confusion Assessment Method for the ICU-7) were measured bid. A cohort of 197 ICU patients with COVID-19 were included. Higher d-dimer (odds ratio [OR], 1.57; 95% CI, 1.17-2.12; p < 0.01) and ferritin quartiles (OR, 1.36; 95% CI, 1.02-1.81; p < 0.01) were associated with greater odds of the composite outcome of delirium/coma next day. d-dimer was associated with greater odds of next day delirium (OR, 1.49; 95% CI, 1.14-1.94; p < 0.01) and coma independently (OR, 1.52; 95% CI, 1.08-2.14; p = 0.017). Higher ferritin quartiles were associated with greater odds of next day delirium (OR, 1.33; 95% CI, 1.04-1.70; p = 0.026) and coma independently (OR, 1.59; 95% CI, 1.14-2.23; p < 0.01). Higher CRP quartiles were associated with coma (OR, 1.36; 95% CI, 1.03-1.79; p = 0.030) and delirium severity the next day (β = 0.30; se, 0.07; p ≤ 0.01).
CONCLUSIONS: Our hypothesis-generating study found d-dimer and ferritin were associated with delirium/coma the following day, as well as delirium and coma independently. CRP was associated with next day coma and delirium severity. Larger studies to validate these results are needed.
参考来源
- Khan SH, Perkins AJ, Chi R, et al. Relationship Among Clinically Obtained Biomarkers of Inflammation, Hypercoagulability, and Macrophage Activation, and Delirium in Critically Ill Patients With COVID-19. Crit Care Explor. 2023. PMID: 36699256. doi:10.1097/CCE.0000000000000851
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。